Biocryst Pharmaceuticals reported $49.68M in Gross Profit on Sales for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Gross Profit On Sales Change
Alnylam Pharmaceuticals ALNY:US $ 177.63M 43.24M
Biocryst Pharmaceuticals BCRX:US $ 49.68M 2.95M
ChemoCentryx CCXI:US 5.25M 3.24M
Chugai Pharma 4519:JP Y 246130M 34420M
Daiichi Sankyo 4568:JP Y 145095M 43967M
Gilead Sciences GILD:US $ 5166M 549M
GlaxoSmithKline GSK:LN 6.14B 283M
Glaxosmithkline GSK:US $ 6135M 283M
Intra Cellular Therapies ITCI:US $ 31.84M 8.71M
IONIS PHARMACEUT IONS:US $ 137.75M 300.03M
Karyopharm Therapeutics KPTI:US $ 46.24M 79.28M
Neurocrine Biosciences NBIX:US $ 306M 1.9M
Ptc Therapeutics PTCT:US $ 138.6M 17.3M
Regeneron Pharmaceuticals REGN:US $ 2560.2M 1408.9M
Sarepta Therapeutics SRPT:US $ 179.39M 9.67M
Ultragenyx Pharmaceutical RARE:US $ 73.83M 6.04M
Vertex Pharmaceuticals VRTX:US $ 1851.7M 26.53M
YTE INCY:US $ 696.02M 128.26M